Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com admin Website Prev Post Gold, Silver and Bitcoin Prices Fall as Fed Caps Off Year with Rate Cut December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts A$3M Placement to Advance High-Impact Workplan for Peru January 23, 2025 Strategic Alliance with Macmahon to Accelerate Redevelopment of Nifty January 23, 2025 Cygnus’ first drill hole returns up to 9.1% Cu outside Resource January 23, 2025